Please assess the completion status of the following clinical trial:

Trial Title: Internal Jugular Vein Compression Collar for Novel Symptomatic Treatment of Venous Pulsatile Tinnitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Male or female age 18 years and older~* Diagnosis of venous pulsatile tinnitus~* Patient at UNC ENT Meadowmont Clinic~Exclusion Criteria~* Increased presence of acid in the body or excessive blood alkalinity~* Open head injury (including in or around the eye) within the past six months~* Pseudotumor cerebri (false brain tumor)~* Presence of brain or spinal shunt~* Known seizure disorder~* Known airway obstruction~* Increased likelihood of blood clotting (coagulation)~* Skin injury, rash, or other abnormality on or around the neck~* age \<18~* unable to provide written consent,~* history of neurological deficits,~* previous cerebral infarction (blockage or narrowing in the arteries supplying blood and oxygen to the brain)~* severe head trauma~* medical contraindications to restriction of blood outflow via the internal jugular veins~* glaucoma (narrow angle or normal tension - increased pressure in the eyes),~* hydrocephalus (increased fluid on the brain)~* recent penetrating brain trauma (within 6 months),~* known carotid hypersensitivity~* known increased intracranial pressure~* idiopathic intracranial hypertension~* known intracranial vascular malformation (e.g. aneurysm, arteriovenous malformation, cavernoma)~* central vein thrombosis~* not tolerating initial fitting of collar.~* Known pregnancy (this is not a direct contraindication but is being made out of an abundance of caution)~* Inability to speak or comprehend English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): Device will be fitted and worn up to two hours daily and participants will log changes in symptom intensity before and during device usage

Based on this trial design, predict the completion outcome and termination type (if applicable).